Skip to content
value.today

SPR Therapeutics, LLC

🇺🇸 Cleveland, Ohio, USAHealth CareFounded 2009
Total raised
$71 M
5 rounds on record
Latest round
$26 M
Jan 2024
First round on record
Oct 2011
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of SPR Therapeutics, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2024$26 MNo. 5$10 to $50 million

SPR Therapeutics, LLC: Raise no. 5, Jan 2024

Investors in this round

39 investors had bought by the notice of Feb 5, 2024: 39 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Series D-1 Preferred Stock and the underlying Common Stock issuable upon its conversion
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ben J. Austin · Executive Officer
  • Josh J. Boggs · Executive Officer
  • Maria E. Bennett · Executive Officer, Director
  • Geoffrey B. Thrope · Director
  • Michael J. Chuisano · Director
  • Nicholas J. Valeriani · Director
  • Robert B. Blankenship · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ben Austin, Cfo. Source: SEC Form D, newest notice filed Feb 5, 2024. Read the notice at the SEC.

equitySEC
Aug 2021$20 MNo. 4$10 to $50 million

SPR Therapeutics, LLC: Raise no. 4, Aug 2021

Investors in this round

1 investor had bought by the notice of Aug 31, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$20 M of $35 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series D Preferred Stock and the underlying Common Stock issuable upon its conversion
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ben J. Austin · Executive Officer
  • Dave B. Youngberg · Executive Officer
  • Josh E. Boggs · Executive Officer
  • Maria E. Bennett · Executive Officer, Director
  • Mark B. Stulz · Executive Officer
  • Geoffrey B. Thrope · Director
  • Michael E. Chuisano · Director
  • Nicholas J. Valeriani · Director
  • Robert B. Blankenship · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • SVB Leerink LLC (CRD 39011) · Boston, MassachusettsSold in all US states

Signed by Maria E. Bennett, President & CEO. Source: SEC Form D, newest notice filed Aug 31, 2021. Read the notice at the SEC.

equitySEC
Jan 2019$8 MNo. 3$2 to $10 million

SPR Therapeutics, LLC: Raise no. 3, Jan 2019

Investors in this round

1 investor had bought by the notice of Jan 30, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $20 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series C-1 Preferred Stock and the underlying Common Stock issuable upon its conversion
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ben J. Austin · Executive Officer
  • Dave C. Youngberg · Executive Officer
  • Josh C. Boggs · Executive Officer
  • Maria E. Bennett · Executive Officer, Director
  • Mark C. Stulz · Executive Officer
  • Geoffrey B. Thrope · Director
  • Les C. Vinney · Director
  • Michael C. Chuisano · Director
  • Nicholas J. Valeriani · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Maria E. Bennett, President & CEO. Source: SEC Form D, newest notice filed Jan 30, 2019. Read the notice at the SEC.

equitySEC
Sep 2017$15 MNo. 2$10 to $50 million

SPR Therapeutics, LLC: Raise no. 2, Sep 2017

Investors in this round

1 investor had bought by the notice of Sep 21, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $19 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series C Preferred Stock and the underlying Common Stock issuable upon its conversion
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$900,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dave C. Youngberg · Executive Officer
  • Josh C. Boggs · Executive Officer
  • Maria E. Bennett · Executive Officer, Director
  • Mark C. Stulz · Executive Officer
  • Geoffrey B. Thrope · Director
  • Les C. Vinney · Director
  • Michael C. Chuisano · Director
  • Nicholas J. Valeriani · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Sword Securities LLC (CRD 32244) · Princeton, New JerseySold in CA, CO, MD, MN, NC, NJ, NY, OH, VT, WV

Signed by Maria E. Bennett, President & CEO. Source: SEC Form D, newest notice filed Sep 21, 2017. Read the notice at the SEC.

equitySEC
Oct 2011$2 MNo. 1$2 to $10 million

SPR Therapeutics, LLC: Raise no. 1, Oct 2011

Investors in this round

17 investors had bought by the notice of Jan 13, 2012: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $0 M still to sell
Smallest investment taken
$20,196
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Ohio

People named in the notice

  • Geoffrey Thrope · Executive Officer, Director
  • Maria Bennett · Executive Officer
  • Len Cosentino · Director
  • Les Vinney · Director
  • Patricia Shrader · Director
  • Ralph Della Ratta, Jr. · Director
  • Warren Grill · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Anna L. Moscioni, Attorney-in-Fact under Power of Attorney dated 10/13/2011. Source: SEC Form D, newest notice filed Jan 13, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • SPR Therapeutics, LLC chose not to state its revenue in its newest notice of a funding round (Feb 2024).

    SEC Form D · Feb 2024

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Feb 2024

That is all the official record says: SPR Therapeutics, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of SPR Therapeutics, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 39 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by SPR Therapeutics, LLC
NameRoleNamed in
Ben J. AustinExecutive officerFeb 2024
Josh J. BoggsExecutive officerFeb 2024
Maria E. BennettExecutive officerFeb 2024
Dave B. YoungbergExecutive officerAug 2021
Josh E. BoggsExecutive officerAug 2021
Mark B. StulzExecutive officerAug 2021
Dave C. YoungbergExecutive officerJan 2019
Josh C. BoggsExecutive officerJan 2019
Mark C. StulzExecutive officerJan 2019
Geoffrey ThropeExecutive officerJan 2012
Maria BennettExecutive officerJan 2012
Geoffrey B. ThropeDirectorFeb 2024
Maria E. BennettDirectorFeb 2024
Michael J. ChuisanoDirectorFeb 2024
Nicholas J. ValerianiDirectorFeb 2024
Robert B. BlankenshipDirectorFeb 2024
Michael E. ChuisanoDirectorAug 2021
Les C. VinneyDirectorJan 2019
Michael C. ChuisanoDirectorJan 2019
Geoffrey ThropeDirectorJan 2012
Len CosentinoDirectorJan 2012
Les VinneyDirectorJan 2012
Patricia ShraderDirectorJan 2012
Ralph Della Ratta, Jr.DirectorJan 2012
Warren GrillDirectorJan 2012